However, the mechanism of lenvatinib and sorafenib combined with PD-1 inhibitors is different, the former can specifically reduce the abundance of tumor Treg cells (Torrens et al., 2021), while the latter has the effect of directly inhibiting the activation of M2 macrophages (Sprinzl et al., 2015). This evidence concerns the gene PDCD1 and neoplasm.